Therapeutic angiogenesis in Buerger’s disease: reviewing the treatment landscape
Open Access
- 30 January 2022
- journal article
- review article
- Published by SAGE Publications in Therapeutic Advances in Rare Disease
- Vol. 3
Abstract
Thromboangiitis obliterans, also known as Buerger’s disease, is a rare inflammatory vasculitis that predominantly develops in smokers and characteristically affects the small- and medium-sized peripheral arteries and veins. Patients typically present with extremity claudication, but symptoms may progress to rest pain and tissue loss, especially in those unable to abstain from tobacco use. Unfortunately, traditional medical treatments are largely ineffective and due to the small caliber of affected vessels and lack of suitable distal targets or venous conduits, endovascular and open surgical approaches are often not possible. Eventually, a significant number of patients require major amputation. For these reasons, much research effort has been made in developing techniques of therapeutic angiogenesis to improve limb perfusion, both for atherosclerotic peripheral arterial disease and the smaller subset of patients with critical limb ischemia due to Buerger’s disease. Neovascularization in response to ischemia relies on a complex interplay between the local tissue microenvironment and circulating stem and progenitor cells. To date, studies of therapeutic angiogenesis have therefore focused on exploiting known angiogenic factors and stem cells to induce neovascularization in ischemic tissues. This review summarizes the available clinical data regarding the safety and efficacy of various angiogenic therapies, notably injection of naked DNA plasmids, viral gene constructs, and cell-based preparations, and describes techniques for potentiating in vivo efficacy of gene- and cell-based therapies as well as ongoing developments in exosome-based cell-free approaches for therapeutic angiogenesis. Plain Language Title and Summary: A review of available and emerging treatments for improving blood flow and wound healing in patients with Buerger’s disease, a rare disorder of blood vessels Buerger’s disease is a rare disorder of the small- and medium-sized blood vessels in the arms and legs that almost exclusively develops in young smokers. Buerger’s disease causes inflammation in arteries and veins, which leads to blockage of these vessels and reduces blood flow to and from the extremities. Decreased blood flow to the arms and legs can lead to development of nonhealing wounds and infection for which some patients may eventually require amputation. Unfortunately, traditional medical and surgical treatments are not effective in Buerger’s disease, so other methods for improving blood flow are needed for these patients. There are several different ways to stimulate new blood vessel formation, both in humans and animal models. The most common treatments involve injection of DNA or viruses that express genes related to blood vessel formation or, alternatively, stem cell–based treatments that help regenerate blood vessels and repair wound tissue. This review explores how safe and effective these various treatments are and describes recent research developments that may lead to better therapies for patients with Buerger’s disease and other vascular disorders.Keywords
This publication has 97 references indexed in Scilit:
- Reduced circulating endothelial progenitor cells in thromboangiitis obliterans (Buerger’s disease)Vascular Medicine, 2013
- Long-Term Follow-Up Evaluation of Results From Clinical Trial Using Hepatocyte Growth Factor Gene to Treat Severe Peripheral Arterial DiseaseArteriosclerosis, Thrombosis, and Vascular Biology, 2012
- Activation of cytokines corroborate with development of inflammation and autoimmunity in thromboangiitis obliterans patientsClinical and Experimental Immunology, 2012
- Circulating Angiogenic Factors in Patients with Thromboangiitis ObliteransPLOS ONE, 2012
- Critical Reevaluation of Endothelial Progenitor Cell Phenotypes for Therapeutic and Diagnostic UseCirculation Research, 2012
- Effect of fibroblast growth factor NV1FGF on amputation and death: a randomised placebo-controlled trial of gene therapy in critical limb ischaemiaThe Lancet, 2011
- Molecular mechanisms and clinical applications of angiogenesisNature, 2011
- Identification of E-selectin as a Novel Target for the Regulation of Postnatal NeovascularizationAnnals of Surgery, 2010
- Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cellsBiochemical and Biophysical Research Communications, 1989
- Tumor Angiogenesis: Therapeutic ImplicationsNew England Journal of Medicine, 1971